Zevra Therapeutics, Inc. Common Stock
Here’s whether Zevra Therapeutics, Inc. Common Stock (ZVRA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+2.94% over 10 days). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 21 — oversold; weak 1-year return of -18.4%; 3-month momentum negative (-5.5%). Currently 36.6% off its 52-week high. Score: -5/7.
ZVRA is trading below its 200-day MA ($10.13) — a key warning sign the longer-term trend is under pressure. An RSI of 20.9 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -18.4% compares to +16.5% for SPY (trailed the market by 34.9%). The current 36.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.